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The majority of patients with community-acquired pneumonia are at low risk for short-term mortality or serious 
morbidity and are increasingly managed in the outpatient setting. Efforts to improve the quality of care for these 
patients will need to measure patient outcomes such as disease-specific symptom resolution. The aims of this study 
were to (1) develop a self-administered daily version of a symptom questionnaire for patients with pneumonia, (2) 
measure the reliability of this instrument, and (3) provide estimates for recovery rates based on symptom resolution 
in a cohort of low-risk patients with community-acquired pneumonia. 
This study was conducted as part of a prospective study of a new emergency department protocol for pneumonia 
at the Massachusetts General Hospital. Eligible study subjects included all adult patients with pneumonia presenting 
to the emergency department with a predicted low risk of short-term mortality. The main outcome measures were 
based on a new five item symptom questionnaire which rates the severity of cough, fatigue, dyspnea, myalgia, and 
fever. The questionnaires were self-administered on days O-7, 14; 21 and 28 from the time of diagnosis of 
pneumonia. The symptom questions were also administered during patient interviews on days 0, 7, 14 and 28 in 
order to assess the questionnaire’s reliability. 
Of the 166 eligible patients, 134 (81%) consented to participate in this study. The mean intra-class reliability 
coefficient of the symptom questionnaire was 0.75. The median times to resolution of individual symptoms ranged 
from 3 days for fever to 14 days for cough and fatigue. Thirty-five percent of patients had at least one symptom still 
present at the end of the 28-day study period. 
We found that a daily self-report questionnaire is a reliable measure of symptom resolution for patients with 
pneumonia. Full resolution of symptoms takes more than 28 days for a significant proportion of patients with 
pneumonia. 
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Introduction 
The majority of patients with community-acquired pneu- 
monia are at low risk for short-term mortality or serious 
morbidity from their illness (1,2). As a result, efforts to 
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improve the quality of care for these patients will need to 
target alternative outcomes, such as improvement in func- 
tional health status, time to resdlution of symptoms, and 
overall satisfaction with care (3). However; such outcomes 
have rarely been collected in studies of pneumonia (4). 
Previously, we have shown that the time to symptom 
resolution in patients with pneumonia is a valid measure of 
recovery in low risk patients (5). In the current study we 
were interested in whether patients could reliably self- 
administer a symptom questionnaire over the course of 
their illness, thus providing a convenient and relatively 
inexpensive means of monitoring patient outcomes for this 
illness. While such symptom diaries have been used in 
several studies of outcomes for other respiratory infections 
such as acute bronchitis (6,7), sinusitis (8), and the common 
cold (9), these diaries have rarely been tested for their 
reliability. Moreover, no such self-report questionnaires 
have been developed for patients with pneumonia. 
The aims of the current study were to (1) develop a 
self-administered daily version of a symptom questionnaire 
‘0 1998 W. B. SAUNDERS COMPANY LTD 
1138 J. P. METLAY ET AL. 
for patients with pneumonia, (2) measure the reliability of 
this instrument, and (3) provide estimates for recovery rates 
based on symptom resolution in a cohort of low-risk 
patients with community-acquired pneumonia. 
Methods 
This study was conducted as part of a prospective study of 
outcomes in patients with community-acquired pneumonia 
who were managed under a new outpatient triage protocol 
at the Massachusetts General Hospital in Boston, 
Massachusetts (10). The protocol was designed to facilitate 
outpatient management of those patients with pneumonia 
who presented to the hospital emergency department and 
were predicted to be at low risk for short-term mortality. 
For each eligible case, the protocol included providing 
physicians and patients with mortality risk information, 
enhanced visiting nurse services, and a free IO-day supply of 
the antibiotic clarithromycin. The study was approved by 
the Subcommittee on Human Studies of the Massachusetts 
General Hospital. 
STUDY POPULATION 
Eligible study subjects included all patients presenting 
to the emergency department with community-acquired 
pneumonia from 1 April 1996 to 28 February 1997. Inclu- 
sion criteria included age 18-84 years, symptoms suggestive 
of pneumonia (including cough, dyspnoea, change in 
sputum, pleuritic chest pain, myalgia or fatigue), and a new 
infiltrate on chest radiography. Exclusion criteria included 
recent hospitalization within the preceding 10 days, current 
nursing home residence, chronic immunosuppression 
(including HIV infection), pregnancy, severe psychosocial 
problems or homelessness compromising follow-up, severe 
neuromuscular diseases, inability to take oral medications, 
and chronic oxygen dependence or hypoxia at the time of 
presentation. For patients meeting eligibility requirements, 
a pneumonia severity index (PSI) score was calculated (1). 
This severity score predicts short-term mortality for 
patients with community-acquired pneumonia and permits 
the identification of patients at low risk (~2.8%). Patients 
categorized as greater than low risk for short term mortality 
were excluded from this study. 
During the enrollment period of the study, 826 consecu- 
tive patients met screening criteria for pneumonia. Of 
these, 576 (70%) were excluded, many for multiple reasons. 
Major exclusions included hypoxia (n=220), age over 84 
years (n= 123), inability to take oral medications (pz= 119), 
immunosuppression (n = 112) severe psychosocial problems 
(n= 102) and recent hospitalization (n=98). Of the remain- 
ing 250 patients, 166 (66%) were predicted to be low risk 
and were eligible for this study. 
OUTCOMES MEASURES 
A new five-item self-administered daily symptom question- 
naire was developed for this study based on results from a 
prior study of symptoms in patients with pneumonia (5,ll) 
as well as the results from detailed symptom questionnaires 
completed by a pilot group of low-risk patients with 
pneumonia. Items were selected based on both their 
measured frequency and their reported impact on the 
recovery from pneumonia. The study questionnaire rated 
the severity of cough, fatigue, dyspnea., myalgia, and fever 
on a six point adjectival scale (O=absent to 5=severe). The 
questionnaire was administered in a diary format which was 
distributed to patients at the time of study enrollment and 
included pre-dated entries for days ‘0 to 7, 14, 21, and 28 
from the time of diagnosis. Patients were instructed in the 
method for completing the diary entries and were reminded 
to complete the diaries at follow-up telephone interviews. 
Patients returned the diaries by mail after the 1 month 
follow-up. All returned symptom questionnaires were 
evaluated on a 3-point quality scale by one of the study 
investigators (L.H.B.) (1 =no entries missing or miscoded, 
2= one-two entries missing or miscoded, 3 =more than two 
entries missing or miscoded). Patients who did not return 
the diary after 1 month received telephone reminders to 
return their completed diaries to the study center. 
In addition, symptom questions identical to those in the 
patient diaries were administered by telephone interview at 
1, 2, and 4 weeks from the time of diagnosis. The interviews 
were conducted by one of the study investigators (L.H.B.) 
or a trained research nurse. Baseline clinical and socio- 
demographic data were obtained by patient interview and 
chart abstraction at the time of study enrollment. 
1 ‘, 
DATA ANALYSIS 
Patient characteristics were compared between enrolled 
study patients and non-enrolled eligible patients for demo- 
graphic and clinical characteristics, using Fisher’s exact test 
for binomial variables and the Wilcoxon rank sum test for 
continuous variables. Time to resolution of individual 
symptoms was calculated based on the first day that a 
symptom was scored as 0 (‘absent’) or 1 (‘mild’), on the 
5-point scale. For statistical analyses, patients with un- 
resolved symptoms were censored at day 28 and patients 
with missing entries at the start of the study period were 
similarly censored unless subsequent entries recorded the 
presence of individual symptoms so that a time to resolu- 
tion could be reliably assigned. A Kaplan-Meier survival 
analysis (12) was used to calculate the rate of resolution of 
each individual symptom. Similarly, a median time to 
resolution of all symptoms was calculated based on the 
survival analysis. 
A symptom score was calculated for each patient at study 
entry and at each follow-up time point based on the sum of 
the five symptom severity ,scales (equally weighted) and 
transformed to a O-100 scale by direct. multiplication. 
Test-retest reliability was based on the intra-class corre- 
lation coefficients between the symptoms scores calculated 
based on the results of self administered and interviewer 
administered questionnaires at each time point (days 0, 7, 
14, and 28). This design was chosen because ‘of the antici- 
pated rapid rate of change of the symptom’. responses, 
necessitating readministration of the question’naire within a 
SYMPTOMS RESOLUTION IK PNEUMONIA 1139 
TABLE 1. Baseline demographic and clinical characteristics of enrolled and non-enrolled study 
patients with pneumonia 
Characteristic 
Study population 
rz=126 
Remaining eligible population* 
n=40 P-value? 
Age, mean 52.1 55.0 0.48 
Gender, % female 45.2 65.0 0.045 
Smokers, % 27.0 15.0 0.14 
COPD, %$ 11.1 10.0 1.0 
Asthma, % 12.7 10.0 0.79 
Outpatient treatment, % 55.6 60 0.72 
PSI, means 55.2 54.8 0.88 
*Remaining patients include those eligible patients who did not consent to :be in the follow-up study 
(~2~32) and those enrolled patients who did not return their symptom diaries (fz=8). 
‘yBased on two-tailed Fisher’s exact test (binary variables) or Wilcoxon rank sum test (continuous 
variables). 
tHistory of chronic obstructive pulmonary disease based on chart documentation. 
@SI is the pneumonia severity index calculated at the time of study enrollment as previously 
described (1,lO). 
maximum 2-3 day period. The intra-class correlation 
coefficients were calculated using a general linear model for 
analysis of variance (ANOVA) (13). 
Results 
PATIENT CHARACTERISTICS 
Of the 166 patients with community-acquired pneumonia 
who were eligible for this study, 134 (81%) agreed to 
participate in the symptom follow-up study. Of these, 126 
patients (94%) completed and returned study symptom 
diaries and were included in this study. The study popula- 
tion was similar to the remaining eligible population in age, 
smoking history, presence of pulmonary comorbidities, and 
severity of illness. However, the study population had a 
smaller proportion of females compared to the non- 
enrolled population (Table 1). Overall, 56% of the study 
patients were discharged from the emergency department 
and treated for pneumonia on an outpatient basis. The 
remaining hospitalized patients had a median length of stay 
of 4 days with a mortality rate of 0% at 4 weeks of 
follow-up. Four percent of the admitted patients required 
admission to an intensive care unit. 
RELIABILITY OF SELF-ADMINISTERED 
SYMPTOM QUESTIONNAIRES 
The majority of returned symptom questionnaires were 
completed in their entirety. Overall, 81% of the completed 
questionnaires had no missing dates of entry or incorrectly 
coded responses. In order to assess test-retest reliability of 
the symptom questionnaire, we compared responses from 
the symptom diary to responses from the same symptom 
questionnaire administered by telephone at approximately 
similar time points. These comparisons were based on 
calculated symptom severity scores for each time point. The 
intra-class reliability coefficient for the symptom severity 
score was highest at day 0, and ranged from 0.60 to 0.88 
depending on the time of administration, with an average of 
0.75 (Table 2). The mode of adminislration of the symptom 
questionnaire (diary KY. telephone interview) did not have a 
statistically significant effect on the calculated symptom 
scores at any time point. 
TIME COURSE OF SYMPTOM RESOLUTION 
The majority of patients reported the presence of each of 
the five symptoms at the time of diagnosis with pneumonia. 
Fatigue, cough, myalgia, fever, and dyspnoea were reported 
by 98%, 94%, 85%, 80%: and 74% of patients, respectively, 
at the time of diagnosis. Symptoms resolved over a variable 
period of time. The median time to resolution for fever was 
3 days, for myalgia was 5 days, for dyspnoea was 6 days, 
and for both cough and fatigue were both 14 days. The 
proportion of patients with unresolved symptoms by day 28 
ranged from 4% for fever to 26% for fatigue (Table 3). 
We defined symptomatic cure as the time to resolution of 
all five symptoms. The median time to symptomatic cure 
was 21 days (inter-quartile range 21-28 days). Symptom 
resolution proceeded over the course of the entire 28-day 
period with a significant proportion of patients (35%) still 
with unresolved symptoms at the end of this study period 
(Fig. 1). 
Discussion 
A self-administered daily symptom questionnaire is a sim- 
ple and reliable method for measuring the time to symptom 
resolution in patients with community-acquired pneumo- 
nia. The information from these questionnaires correlated 
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TABLE 2. Test-retest reliability of symptom questionnaire 
Mean score from symptom questionnaire* 
Time of assessment Self-administered Interview Reliability coefficient? 
Day 0 69.7 68.1 0.88 
Day 7 32.3 20.8 0.60 
Day 14 25.9 ‘26.8 0.73 
Day 28 18.8 21.1 0.78 
Average - 6.75 
*Scores were calculated for both modes of administration at each time point based on the sum of the 
severity scores for all five symptoms (range for each severity scale O-5) and then transformed to a 
O-100 scale by direct multiplication. 
TBased on intra-class reliability coefficient, comparing scores from self-administered and interview 
administered symptom questionnaires at each time point. 
TABLE 3. Median time to resolution of symptoms in patients with pneumonia* 
Symptom 
Inter-quartile range % With unresolved symptom 
Time to resolution (days) (days) at day 28 
Fever 3 24 3.5 
Myalgia 5 4-6 13.5 
Dyspnea 6 5-14 16.8 
Cough 14 7-21 19.9 
Fatigue 14 6-21 25.7 
All symptoms 21 21-28 35.0 
*Median time to symptom resolution and inter-quartile range were estimated by the Kaplan-Meier 
survival analysis. 
well with .information obtained through telephone inter- 
views as reflected in intra-class reliability coefficients which 
were often in the range considered excellent (>0.75) (13). 
The time to resolution of symptoms was variable ranging 
from less than 1 week for symptoms of fever and myalgia, 
to at least 2 weeks or more for symptoms of cough and 
fatigue. Approximately one-third’ of these pneumonia 
patients had at least one symptom still present at the end of 
the 4-week study period. 
Information on the time to symptom resolution for 
patients with pneumonia should be valuable for both 
current clinical practice and future clinical research. If 
patients were informed that the time to full symptom 
resolution may often be greater than’ 1 month, patient 
expectations and need for follow-up care might be 
improved. In a prior study, we demonstrated that patients 
with delayed time to symptom resolution had significantly 
higher rates of return visits to physicians for pneumonia- 
related reasons (5). In the current study, time to overall 
symptom resolution was shorter in patients who did not 
have any follow-up physician visits during the 4 weeks 
compared to those who did have physician visits, but this 
difference did not reach statistical significance (results not 
shown). In addition, time to symptom resolution may be a 
useful measure of the relative efficacy of different antibiotic 
therapies. However, the majority of patients in this study 
were treated with the drug clarithromycin, preventing any 
comparative analyses. Future studies of community- 
acquired pneumonia should consider time to symptom 
resolution as one of several important outcomes in 
comparing different treatment strategies. 
In our previous study of outcomes from pneumonia, the 
proportions of patients reporting symptoms at 30 days 
from the time of diagnosis ranged from 65% for fatigue to 
36% for dyspnoea, and the proportions reporting moderate 
to severe symptoms ranged from 28% (fatigue) to 7% 
(dyspnoea) (5), which are higher than those measured in the 
current study. However, the patients from that earlier study 
were identified as low-risk based only on their severity of 
illness score. The current study population was assembled 
from a group of low severity patients who met additional 
criteria for outpatient therapy for pneumonia and may have 
been less ill compared to this earlier study group. We have 
separately reported direct comparisons between these two 
groups, demonstrating that the differences in symptom 
resolution were not significant after adjusting for differ- 
ences in symptom reporting at baseline (10). Another study 
of pneumonia resolution, which included otherwise healthy 
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FIG. 1. The cumulative proportion of patients with resolved symptoms from the time of pneumonia diagnosis. The 
proportions are based on a Kaplan-Meier survival analysis. Error bars indicated the upper 95% CI for estimation of the 
proportion with resolution of all symptoms a each time point. 
military recruits in Finland, found that the mean time to 
resolution of cough ranged from as short as 5 days (for 
patients with mycoplasma pneumonia) to as long as 8 days 
(for patients with pneumococcal pneumonia) (14). We do 
not have information on microbial etiology for the majority 
of patients in our study. While 10% of patients had definite 
or probable pneumococcal pneumonia, there were too few 
patients in any other etiological group to permit any 
meaningful comparisons within this study. 
Several limitations of this study should be noted. First, 
patients enrolled in this study represented a select group 
who had sufficiently low severity of illness and high social 
support that they would be considered safe for outpatient 
therapy. To the degree that other patients with pneumonia 
are sicker and more impaired by their symptoms, the results 
of this study would be an underestimation of the time to 
symptom resolution. However, time to resolution of 
symptoms would be a less important outcome measure for 
those severely ill patients with pneumonia because of their 
higher risk for short-term mortality and serious morbidity. 
Second, although our study suggested good reliability for 
the symptom diary, we have no way to confirm that daily 
entries actually occurred on the appropriate days. One 
study, using both written and electronic diaries in asthma 
patients, demonstrated that retrospective completion of 
diary entries occurred in < 10% of all diary entries (15). 
Finally, our definition of symptom resolution (i.e. when the 
symptom was recorded as absent or very mild) may be 
viewed as arbitrary. For example, patients with chronic 
symptoms, including patients with chronic lung diseases 
such as asthma and chronic bronchitis, may always report 
symptoms at moderate to severe levels while other patients 
may feel that symptoms are not resolved until they are 
completely absent. Attempts to establish pre-illness 
symptom baselines for patients with acute illnesses are, 
however, subject to significant recall bias and did not 
provide consistent information in this study. Further 
research in the area of establishing criteria for defining 
symptom resolution is needed. 
In conclusion, a patient self-administered daily question- 
naire is a reliable method for obtaining information on the 
time to symptom resolution for patients with pneumonia. It 
would be useful to collect such measures for patients with 
pneumonia of different severity and in different popula- 
tions. Such information may be used by physicians to better 
inform their patients about the natural history of their 
illness. 
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